Who are Bepreve's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): bepotastine besilate ophthalmic solution, Lastacaft, Xyzal, Clarinex, Astelin, Semprex-D.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bepotastine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Bepreve — Competitive Intelligence Brief

Bepreve (BEPOTASTINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histamine-1 Receptor Antagonist. Area: Other.

marketed Histamine-1 Receptor Antagonist H1-receptor, mast cells Other Small molecule Live · refreshed every 30 min

Target snapshot

Bepreve (BEPOTASTINE) — Bausch Health. Bepotastine blocks H1 receptors and inhibits histamine release from mast cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bepreve TARGET	BEPOTASTINE	Bausch Health	marketed	Histamine-1 Receptor Antagonist	H1-receptor, mast cells	2009-01-01
bepotastine besilate ophthalmic solution	bepotastine besilate ophthalmic solution	Bausch & Lomb Incorporated	marketed		H1-receptor, mast cells
Lastacaft	ALCAFTADINE	AbbVie	marketed	Histamine-1 Receptor Antagonist [EPC]	Histamine H1 receptor	2010-01-01
Xyzal	LEVOCETIRIZINE	Sanofi	marketed	Histamine-1 Receptor Antagonist	Histamine H1 receptor	2007-01-01
Clarinex	desloratadine	Generic (originally Schering-Plough/MSD)	marketed	Histamine-1 Receptor Antagonist [EPC]	5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	2001-12-21
Astelin	AZELASTINE	Bayer	marketed	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1996-01-01
Semprex-D	ACRIVASTINE	Auxilium Pharms Inc	marketed	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histamine-1 Receptor Antagonist class)

Bayer · 3 drugs in this class
Auxilium Pharms Inc · 1 drug in this class
Bausch Health · 1 drug in this class
Mcneil · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bepreve — Competitive Intelligence Brief. https://druglandscape.com/ci/bepotastine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab